Market research reports on: Pharmaceutical manufacture, cancer, oncology, prevention and treatment, therapeutics, vaccines, clinical studies, drug delivery, immunology, immunotherapy and others.
Let's ConnectGlobal Markets for Asthma and COPD Drugs
The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.
Genitourinary Drugs: Technologies and Global Markets
The total market for genitourinary drugs is projected to increase from $26.5 billion in 2011 to $30.7 billion in 2016 at a compound annual growth rate (CAGR) of 3% for a period of five years, from 2011 to 2016.
Drugs for Treating Congestive Heart Failure: Global Markets
The global market for congestive heart failure pharmaceuticals was valued at nearly $11.2 billion in 2010. This market is expected to reach nearly $12.2 billion in 2011 and $18.6 billion in 2016, a compound annual growth rate (CAGR) of 8.9% between 2011 and 2016.
Global Markets for Marine-Derived Pharmaceuticals
The global market for marine-derived drugs by type was around $4.8 billion in 2011, which is expected to be around $5.3 billion in 2012. This global market is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% for the five year period of 2011 to 2016.
Markets for Emerging Pharmaceutical Technologies
As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.
Emerging Regional Markets for Therapeutic Drugs
The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.
The Clinical Trials Business
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014.
Therapeutic Drugs for Central Nervous System (CNS) Disorders: Tec...
This study provides a comprehensive analysis of central nervous system therapies on a global basis. It provides a range of information, from detailed product analyses within disease sub-segments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the central nervous system sector.
Oncology Adjuvants: Technologies and Global Markets
This report covers the current status of the global oncolytic adjuvant marketplace and assess its growth potential over the five-year period from 2010 to 2015
Cardiovascular Therapeutic Drugs: Technologies and Global Markets
This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Includes forecasts through 2015
Osteoporosis Drugs: Technologies and Global Markets
This study describes the industry structure and major participants in the osteoporosis drugs market, market dynamics and competitive aspects, current developments and future market trends, to assist in understanding the market and identifying areas of commercial interest and potential in osteoporosis. Includes forecasts through 2014
Autacoids and Related Drugs: Technologies and Global Markets
This BCC report presents a comprehensive analysis of the current market for autacoids and related drugs and its future direction. It also examines the x biologic activity and usage of autacoids in the treatment of various diseases. Includes forecasts through 2015
Therapies for Depressive and Anxiety Disorders
Research report on the Global Market for Therapies for Depressive and Anxiety Disorders. Includes forecasts through 2014
Rare Disease Diagnostics: Technologies and Global Markets
This report provides an overview of rare disease diagnostic technologies, applications, industries, initiatives, patents and companies. The market for rare disease diagnostic products and services is given for 2023 and 2024, and then forecast through 2029.
Laboratory Animal Models, 3D Cultures and Organoids: Global Markets
This report provides detailed exposure to the laboratory animal model, 3D cell culture and organoids market. This report will highlight current and future market potential and a detailed analysis of the competitive environment.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
This report provides an overview of the current regulatory environment, possible applications for breakthrough therapy designation (BTD) in other parts of the world, and ways to combine BTD with early access to medication programs to enhance patient access to medication for the treatment of rare diseases and high unmet clinical needs.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report provides an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2023.
High-Throughput Screening: Technologies and Global Markets
This report provides an analysis of the global high-throughput screening (HTS) market. It includes major market dynamics and current trends within the industry.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
This report encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics.
Neurology Market: A BCC Research Overview
This report covers therapeutics used in the treatment of neurological disorders. It highlights the current and future market potential of neurology medicines.